Low Pretreatment Viral Loads in Infants With HIV in an Era of High-maternal Antiretroviral Therapy Coverage.
Adult
Anti-Retroviral Agents
/ administration & dosage
Cohort Studies
Female
HIV Infections
/ drug therapy
Humans
Infant, Newborn
Infectious Disease Transmission, Vertical
/ statistics & numerical data
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Viral Load
/ statistics & numerical data
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
15
9
2020
medline:
26
8
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
With expansion of antiretroviral therapy (ART) programs, transmission rates are low but new infant infections still occur. We investigated predictors of pre-ART viral load (VL) and CD4+ T-cell counts and percentages in infants diagnosed with HIV at birth in a setting with high coverage of maternal ART and infant prophylaxis. As part of an early treatment study, 97 infants with confirmed HIV-infection were identified at a hospital in Johannesburg, South Africa. Infant VL and CD4+ T-cell parameters were measured before ART initiation. Data were collected on maternal characteristics, including VL, CD4+ T-cell counts and ART, and infant characteristics, including sex, birth weight, and mode of delivery. Pre-ART, median infant VL was 28,405 copies/mL [interquartile range (IQR): 2515-218,150], CD4+ T-cell count 1914 cells/mm (IQR: 1474-2639) and percentage 40.8% (IQR: 32.2-51.2). Most (80.4%) infants were born to mothers who received ART during pregnancy and 97.9% of infants received daily nevirapine prophylaxis until ART initiation at median of 2 days of age (IQR: 1-7). Infant pre-ART VL was more likely to be ≥1000 copies/mL when their mothers had VL ≥1000 copies/mL [Odds Ratio (OR): 6.88, 95% confidence interval (CI): 2.32-20.41] and was higher in boys than girls (OR: 3.29, 95% CI: 1.07-9.95). Lower maternal CD4+ T-cell count (<350 cells/mm) was associated with lower infant CD4+ T-cell count (<1500 cells/mm) (OR: 3.59, 95% CI: 1.24-10.43). Pre-ART VL and CD4+ T-cell parameters of intrauterine-infected infants were associated with VL and CD4+ T-cell counts of their mothers. Maternal ART during pregnancy may begin treatment of intrauterine infection and may mask the severity of disease in infected infants identified in the current era with high-maternal ART coverage.
Sections du résumé
BACKGROUND
With expansion of antiretroviral therapy (ART) programs, transmission rates are low but new infant infections still occur. We investigated predictors of pre-ART viral load (VL) and CD4+ T-cell counts and percentages in infants diagnosed with HIV at birth in a setting with high coverage of maternal ART and infant prophylaxis.
METHODS
As part of an early treatment study, 97 infants with confirmed HIV-infection were identified at a hospital in Johannesburg, South Africa. Infant VL and CD4+ T-cell parameters were measured before ART initiation. Data were collected on maternal characteristics, including VL, CD4+ T-cell counts and ART, and infant characteristics, including sex, birth weight, and mode of delivery.
RESULTS
Pre-ART, median infant VL was 28,405 copies/mL [interquartile range (IQR): 2515-218,150], CD4+ T-cell count 1914 cells/mm (IQR: 1474-2639) and percentage 40.8% (IQR: 32.2-51.2). Most (80.4%) infants were born to mothers who received ART during pregnancy and 97.9% of infants received daily nevirapine prophylaxis until ART initiation at median of 2 days of age (IQR: 1-7). Infant pre-ART VL was more likely to be ≥1000 copies/mL when their mothers had VL ≥1000 copies/mL [Odds Ratio (OR): 6.88, 95% confidence interval (CI): 2.32-20.41] and was higher in boys than girls (OR: 3.29, 95% CI: 1.07-9.95). Lower maternal CD4+ T-cell count (<350 cells/mm) was associated with lower infant CD4+ T-cell count (<1500 cells/mm) (OR: 3.59, 95% CI: 1.24-10.43).
CONCLUSIONS
Pre-ART VL and CD4+ T-cell parameters of intrauterine-infected infants were associated with VL and CD4+ T-cell counts of their mothers. Maternal ART during pregnancy may begin treatment of intrauterine infection and may mask the severity of disease in infected infants identified in the current era with high-maternal ART coverage.
Identifiants
pubmed: 32925542
doi: 10.1097/INF.0000000000002897
pmc: PMC7722046
mid: NIHMS1623551
pii: 00006454-202101000-00015
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-59Subventions
Organisme : NICHD NIH HHS
ID : U01 HD080441
Pays : United States
Références
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016. 2016. Available at: http://www.who.int/hiv/pub/arv/arv-2016/en/ Accessed September 2, 2020.
Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385–393.
UNICEF UNAIDS and WHO. Key considerations for programming and prioritization. Going the ‘last mile’ to EMTCT: a road map for ending the HIV epidemic in children. 2020. Available at: http://www.childrenandaids.org/sites/default/files/2020-02/Last-Mile-To-EMTCT_WhitePaper_UNICEF2020.pdf . Accessed May 9, 2020.
https://www.unaids.org/en/regionscountries/countries/southafrica Accessed March 2, 2020.
UNAIDS: AIDSInfo. Available at: https://aidsinfo.unaids.org/
Kuhn L, Strehlau R, Shiau S, et al.; LEOPARD Study Team. Early antiretroviral treatment of infants to attain HIV remission. EClinicalMedicine. 2020;18:100241.
Abrams EJ, Wiener J, Carter R, et al.; Perinatal AIDS Collaborative Transmission Study (PACTS) Group. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS. 2003;17:867–877.
Obimbo EM, Wamalwa D, Richardson B, et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr. 2009;51:209–215.
Ioannidis JP, Tatsioni A, Abrams EJ, et al. Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an international meta-analysis. AIDS. 2004;18:99–108.
Tobin NH, Aldrovandi GM. Immunology of pediatric HIV infection. Immunol Rev. 2013;254:143–169.
Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336:1337–1342.
Reitz C, Coovadia A, Ko S, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis. 2010;201:1121–1131.
Abrams EJ, Woldesenbet S, Soares Silva J, et al. Despite access to antiretrovirals for prevention and treatment, high rates of mortality persist among HIV-infected infants and young children. Pediatr Infect Dis J. 2017;36:595–601.
Domínguez-Rodríguez S, Tagarro A, Palma P, et al. Reduced time to suppression among neonates with HIV initiating antiretroviral therapy within 7 days after birth. J Acquir Immune Defic Syndr. 2019;82:483–490.
Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. Clin Infect Dis. 2020.ciaa028. doi: 10.1093/cid/ciaa028. [Online ahead of print]
doi: 10.1093/cid/ciaa028.
Mazanderani AH, Moyo F, Kufa T, et al. Brief report: declining baseline viremia and escalating discordant HIV-1 confirmatory results within South Africa’s early infant diagnosis program, 2010-2016. J Acquir Immune Defic Syndr. 2018;77:212–216.
European Collaborative Study. Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys? AIDS. 2002;16:97–104.
Mori M, Adland E, Paioni P, et al. Sex Differences in antiretroviral therapy initiation in pediatric HIV infection. PLoS One. 2015;10:e0131591.
Vieira VA, Zuidewind P, Muenchhoff M, et al. Strong sex bias in elite control of paediatric HIV infection. AIDS. 2019;33:67–75.
Taha TE, Nour S, Kumwenda NI, et al. Gender differences in perinatal HIV acquisition among African infants. Pediatrics. 2005;115:e167–e172.
Frigati L, Wynberg E, Maritz J, et al. Antiretroviral treatment initiated in the first month of life. Pediatr Infect Dis J. 2017;36:584–587.
Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756–761.